Current Situation of Health Care in Women With HBV or HCV Infection

NCT ID: NCT06579313

Last Updated: 2024-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Some of the sociocultural factors may prevent women infected with HBV or HCV benefiting from quality health care. Limited articles have ever reported the situation of health care in women with viral hepatitis. A previous study found that low HCV knowledge was observed in females, which was related to a lower willingness to be treated for HCV. Besides that, in other disease areas like hypertension, studies found that females have less awareness of their disease but have higher control over it compared with males. These findings might reflect the differences in health literacy levels which might influence disease outcomes, healthcare-seeking and adherence to treatment. This research aims to fill the data gaps of the gender differences in cascade of care in HBV and HCV, to facilitate patient activation, especially for women.

So far, data on the current health care status in HBV-infected women is scarce. With the expansion of treatment indications recommended by China CHB guidelines, more female patients will have the opportunity to gain timely and necessary treatment. This study will analyze the cascade of care by observing the duration from diagnosis to treatment and treatment adherence for women. And this knowledge will serve as a guide for interventions for the management of viral hepatitis, as well as effectively finding and activating patients who meet treatment criteria but are not being treated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HBV HCV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HBV cohort

2000 HBsAg positive patients during 2016.7-2019.12

No interventions assigned to this group

HCV cohort

500 HCV Ab positive and HCV RNA positive patients during 2020.7-2023.12

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

HBV Cohort -

* ≥18 years old
* serum HBsAg positive for \>6 months
* Treatment naïve or,
* Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment

HCV Cohort -

* ≥18 years old
* HCV-Ab positive
* HCV RNA positive
* Treatment naïve or,
* Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.

Exclusion Criteria

* HBV/HCV Co-infection
* HIV
* History of hepatic decompensation or hepatocellular carcinoma
* Other carcinoma
* Other severe liver disease
* Severe Comorbidity like cardiovascular disease, diabetes etc.
* Patients who had discontinued previous HCV treatment because of an adverse event.
* Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor
* Patients who had discontinued previous HBV treatment because of an adverse event.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruijin Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Qing Xie

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Honglian Gui

Role: CONTACT

+8613564725017

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IN-US-987-7219

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hepatitis Inequalities Study
NCT06596213 NOT_YET_RECRUITING